Literature DB >> 30605054

Hyperglycemia and Diabetes Induced by Glucocorticoids in Nondiabetic and Diabetic Patients: Revision of Literature and Personal Considerations.

Ceccarelli Elena1, Mattaliano Chiara1, Brazzi Angelica1, Marinetti A Chiara1, Nigi Laura1, Chirico Chiara1, Corallo Claudio1, Fioravanti Antonella1, Giordano Nicola1.   

Abstract

BACKGROUND: Glucocorticoids are powerful and effective anti-inflammatory and immunosuppressive drugs. They have extensive use in the treatment of different diseases, even though their side effects, such as hypertension, osteoporosis and, in particular, diabetes, are well known. They can exacerbate hyperglycemia in patients with diabetes mellitus or facilitate the development of metabolic disease in apparently healthy subjects, the so-called steroid-induced diabetes mellitus. The last one is an independent risk factor for other complications associated with the use of glucocorticosteroids.
OBJECTIVES: We tried to clarify the physiopathology and the correct management of glucocorticoidsinduced diabetes, referring in particular to diabetic patients who have to take such drugs for long periods.
METHODS: A thorough literature search was performed using Pubmed database to cover all relative reports, using combinations of keywords: diabetes mellitus, insulin, glucocorticoids therapy, dipeptidyl peptidase- 4 inhibitors (DPP-4 inhibitor), glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists), sodium-glucose co-transporter-2 inhibitors (SGLT-2 inhibitor), hyperglycemia, glucose-lowering drugs. RESULTS &
CONCLUSION: Glucocorticoids-induced diabetes is a harmful and underestimated problem when the therapeutic program is not correct and well planned. Screening or more stringent monitoring must always be suggested before starting with corticosteroids; moreover, the hypoglycemic therapy should be personalized, based on the severity of hyperglycemia, type of steroid used and patients' comorbidities. All the oral glucose-lowering drugs can be used, but insulin is the most studied drug and the medication recommended for severe hyperglycemia, for patients with pre-existing diabetes or for those patients who have to undergo prolonged therapy over time. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Hyperglycemia; anti-inflammatory; antiproliferative drugs; diabetes mellitus; glucocorticoids; osteoporosis.

Mesh:

Substances:

Year:  2018        PMID: 30605054     DOI: 10.2174/1389201020666190102145305

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  13 in total

1.  Calcineurin inhibitor-associated new-onset diabetes mellitus in chronic kidney disease treatment: a 4-year single-center cross-sectional study in China.

Authors:  Pan Kun-Ming; Chen Can; Xu Qing; Wu Wei; Lv Qian-Zhou; Li Xiao-Yu
Journal:  Eur J Clin Pharmacol       Date:  2021-01-23       Impact factor: 2.953

2.  Looking for the skeleton in the closet-rare genetic diagnoses in patients with diabetes and skeletal manifestations.

Authors:  Avivit Brener; Leonid Zeitlin; Yael Wilnai; Ohad S Birk; Talya Rosenfeld; Efrat Chorna; Yael Lebenthal
Journal:  Acta Diabetol       Date:  2022-02-08       Impact factor: 4.280

3.  Dexamethasone prescribing for cancer pain between palliative care and radiation oncology.

Authors:  Andrew Jeong; Kevin Wade
Journal:  Support Care Cancer       Date:  2022-06-11       Impact factor: 3.359

Review 4.  Nutritional recommendations for patients undergoing prolonged glucocorticoid therapy.

Authors:  Gabriel P Esteves; Bruna Caruso Mazzolani; Fabiana Infante Smaira; Elizabeth Silva Mendes; Gabriela Guimarães de Oliveira; Hamilton Roschel; Bruno Gualano; Rosa Maria R Pereira; Eimear Dolan
Journal:  Rheumatol Adv Pract       Date:  2022-04-21

Review 5.  Preoperative, Intraoperative and Postoperative Corticosteroid Use as an Adjunctive Treatment for Rhegmatogenous Retinal Detachment.

Authors:  Vincenza Bonfiglio; Michele Reibaldi; Iacopo Macchi; Matteo Fallico; Corrado Pizzo; Clara Patane; Andrea Russo; Antonio Longo; Alessandra Pizzo; Giovanni Cillino; Salvatore Cillino; Maria Vadalà; Michele Rinaldi; Robert Rejdak; Katarzyna Nowomiejska; Mario Damiano Toro; Teresio Avitabile; Elina Ortisi
Journal:  J Clin Med       Date:  2020-05-21       Impact factor: 4.241

6.  Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials.

Authors:  Mark C Genovese; Gerd R Burmester; Owen Hagino; Karthinathan Thangavelu; Melitza Iglesias-Rodriguez; Gregory St John; Miguel A González-Gay; Thomas Mandrup-Poulsen; Roy Fleischmann
Journal:  Arthritis Res Ther       Date:  2020-09-09       Impact factor: 5.156

7.  Secondary Membranous Nephropathy. A Narrative Review.

Authors:  Gabriella Moroni; Claudio Ponticelli
Journal:  Front Med (Lausanne)       Date:  2020-12-03

8.  Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein.

Authors:  Nigel Davies; Daniel Hovdal; Nicholas Edmunds; Peter Nordberg; Anders Dahlén; Aleksandra Dabkowska; Marianna Yanez Arteta; Aurel Radulescu; Tomas Kjellman; Andreas Höijer; Frank Seeliger; Elin Holmedal; Elisabeth Andihn; Nils Bergenhem; Ann-Sofie Sandinge; Camilla Johansson; Leif Hultin; Marie Johansson; Johnny Lindqvist; Liselotte Björsson; Yujia Jing; Stefano Bartesaghi; Lennart Lindfors; Shalini Andersson
Journal:  Mol Ther Nucleic Acids       Date:  2021-03-13       Impact factor: 8.886

9.  STOP: an open label crossover trial to study ICS withdrawal in patients with a combination of obesity and low-inflammatory asthma and evaluate its effect on asthma control and quality of life.

Authors:  Jasper H Kappen; Elisabeth F C van Rossum; Jan A Witte; Gert-Jan Braunstahl; Wouter J B Blox; Susan C van 't Westeinde; Johannes C C M In 't Veen
Journal:  BMC Pulm Med       Date:  2022-02-05       Impact factor: 3.317

10.  Significance of serum glucagon-like peptide-1 and matrix Gla protein levels in patients with diabetes and osteoporosis.

Authors:  Fei-Fei Xie; Yu-Fang Zhang; Yan-Fang Hu; Yun-Yun Xie; Xiao-Ying Wang; Shu-Zhen Wang; Bao-Qiang Xie
Journal:  World J Clin Cases       Date:  2022-02-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.